Literature DB >> 10397448

Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors.

E Kökoğlu1, Y Tüter, K S Sandikçi, Z Yazici, E Z Ulakoğlu, H Sönmez, E Ozyurt.   

Abstract

Arachidonic acid is stored in the cell membrane and released when the cell is activated by appropriate stimuli. It is the substrate for prostaglandins. Both experimental and human tumors often synthesize high levels of prostaglandins, most notably prostaglandin E2 (PGE2). Some experiments suggest that these compounds increase tumor growth through their actions on host immunocytes. In this study, 22 patients with various brain tumors and 12 control brain tissues were studied. PGE2 levels in tissue samples were measured by ELISA. Arachidonic acid levels in the plasma membrane of tissue samples were analyzed by capillary gas chromatography. The levels of PGE2 were significantly higher in gliomas (n = 10) and meningiomas (n = 7) compared with control tissues (P = 0.000 and P = 0.000, respectively). Also, PGE2 levels in meningiomas were significantly higher than in gliomas (P = 0.000). Arachidonic acid levels in the plasma membrane of gliomas (n = 9) and meningiomas (n = 6) were significantly higher than in the control tissues (P = 0.000 and P = 0.000, respectively). These results suggest that the increased production of PGE2 may suppress the immune system and play an important role in tumor growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10397448     DOI: 10.1016/s0304-3835(98)00127-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  Analgesic use and the risk of primary adult brain tumor.

Authors:  Kathleen M Egan; Louis B Nabors; Zachary J Thompson; Carrie M Rozmeski; Gabriella A Anic; Jeffrey J Olson; Renato V LaRocca; Sajeel A Chowdhary; Peter A Forsyth; Reid C Thompson
Journal:  Eur J Epidemiol       Date:  2016-02-19       Impact factor: 8.082

2.  Prostaglandins antagonistically control Bax activation during apoptosis.

Authors:  L Lalier; P-F Cartron; C Olivier; C Logé; G Bougras; J-M Robert; L Oliver; F M Vallette
Journal:  Cell Death Differ       Date:  2010-10-22       Impact factor: 15.828

3.  The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal.

Authors:  Joon-Khim Loh; Shiuh-Lin Hwang; Ann-Shung Lieu; Tzuu-Yuan Huang; Shen-Long Howng
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

4.  Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism.

Authors:  Charlotte Andersson; M Rabie Al-Turkmani; Juanito E Savaille; Ragheed Alturkmani; Waddah Katrangi; Joanne E Cluette-Brown; Munir M Zaman; Michael Laposata; Steven D Freedman
Journal:  J Lipid Res       Date:  2008-04-25       Impact factor: 5.922

5.  Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.

Authors:  Ninib Baryawno; Baldur Sveinbjörnsson; Staffan Eksborg; Abiel Orrego; Lova Segerström; Carl Otto Oqvist; Stefan Holm; Bengt Gustavsson; Bertil Kågedal; Per Kogner; John Inge Johnsen
Journal:  Neuro Oncol       Date:  2008-08-20       Impact factor: 12.300

6.  The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.

Authors:  George N Tzanakakis; Elias Krambovitis; Aristidis M Tsatsakis; Michael P Vezeridis
Journal:  Int J Gastrointest Cancer       Date:  2002

7.  Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma.

Authors:  Ersoy Oksuz; Fatmahan Atalar; Gamze Tanırverdi; Ayahan Bilir; Andleeb Shahzadi; Zeliha Yazici
Journal:  J Neurooncol       Date:  2015-10-27       Impact factor: 4.130

Review 8.  The eicosanoid cascade: possible role in gliomas and meningiomas.

Authors:  N Nathoo; G H Barnett; M Golubic
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

9.  Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.

Authors:  Tae-Ho Kim; Young-Il Jeong; Shu-Guang Jin; Jian Pei; Tae-Young Jung; Kyung-Sub Moon; In-Young Kim; Sam-Suk Kang; Shin Jung
Journal:  Int J Nanomedicine       Date:  2011-10-28

Review 10.  Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy.

Authors:  Zahraa F Audi; Zahraa Saker; Mahdi Rizk; Hisham F Bahmad; Sanaa M Nabha; Hayat Harati; Youssef Fares
Journal:  Curr Treat Options Oncol       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.